T1	PROC 44 91	Ensayo para comparar la eficacia y la seguridad
T2	CHEM 95 112	insulina degludec
#1	AnnotatorNotes T2	C3491971; insulin degludec; Amino Acid, Peptide, or Protein · Hormone · Pharmacologic Substance
T3	CHEM 113 124	liraglutida
#2	AnnotatorNotes T3	C1456408; liraglutide; Amino Acid, Peptide, or Protein · Hormone · Pharmacologic Substance
T4	CHEM 134 151	insulina glargina
#3	AnnotatorNotes T4	C0907402; insulin glargine; Amino Acid, Peptide, or Protein · Hormone · Pharmacologic Substance
T5	DISO 167 194	diabetes mellitus de tipo 2
#4	AnnotatorNotes T5	C0011860; Diabetes Mellitus, Non-Insulin-Dependent; Disease or Syndrome
T6	DISO 218 233	Diabetes tipo 2
#5	AnnotatorNotes T6	C0011860; Diabetes Mellitus, Non-Insulin-Dependent; Disease or Syndrome
T7	DISO 259 283	Diabetes Mellitus Tipo 2
#6	AnnotatorNotes T7	C0011860; Diabetes Mellitus, Non-Insulin-Dependent; Disease or Syndrome
T8	DISO 312 339	Diabetes mellitus de tipo 2
#7	AnnotatorNotes T8	C0011860; Diabetes Mellitus, Non-Insulin-Dependent; Disease or Syndrome
T9	PROC 1053 1056	IMC
#8	AnnotatorNotes T9	C0005893; Body mass index procedure; Diagnostic Procedure | C3698309; Measurement of body mass index; Health Care Activity
T10	PROC 427 450	análisis de laboratorio
#9	AnnotatorNotes T10	C0022885; Laboratory Procedures; Laboratory Procedure
T11	PROC 461 472	Tratamiento
#10	AnnotatorNotes T11	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T12	CHEM 484 501	insulina glargina
#11	AnnotatorNotes T12	C0907402; insulin glargine; Amino Acid, Peptide, or Protein · Hormone · Pharmacologic Substance
T13	CHEM 579 596	insulina glargina
#12	AnnotatorNotes T13	C0907402; insulin glargine; Amino Acid, Peptide, or Protein · Hormone · Pharmacologic Substance
T14	CHEM 929 939	metformina
#13	AnnotatorNotes T14	C0025598; metformin; Organic Chemical · Pharmacologic Substance
T15	PROC 1097 1108	Tratamiento
#14	AnnotatorNotes T15	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T16	CHEM 1157 1167	metformina
#15	AnnotatorNotes T16	C0025598; metformin; Organic Chemical · Pharmacologic Substance
T17	CHEM 1248 1255	fármaco
#16	AnnotatorNotes T17	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T18	CHEM 1265 1275	metformina
#17	AnnotatorNotes T18	C0025598; metformin; Organic Chemical · Pharmacologic Substance
T19	CHEM 1278 1295	insulina glargina
#18	AnnotatorNotes T19	C0907402; insulin glargine; Amino Acid, Peptide, or Protein · Hormone · Pharmacologic Substance
T20	CHEM 1321 1331	medicación
#19	AnnotatorNotes T20	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T21	CHEM 1414 1421	glucosa
#20	AnnotatorNotes T21	C0017725; glucose; Biologically Active Substance · Organic Chemical · Pharmacologic Substance
T22	CHEM 1431 1447	corticosteroides
#21	AnnotatorNotes T22	C0001617; Adrenal Cortex Hormones; Hormone · Organic Chemical · Pharmacologic Substance
T23	PROC 1462 1473	Tratamiento
#22	AnnotatorNotes T23	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T24	CHEM 1512 1520	insulina
#23	AnnotatorNotes T24	C0021641; Insulin; Amino Acid, Peptide, or Protein · Hormone · Pharmacologic Substance | C3537244; Insulins; Pharmacologic Substance
T25	CHEM 1554 1562	insulina
#24	AnnotatorNotes T25	C0021641; Insulin; Amino Acid, Peptide, or Protein · Hormone · Pharmacologic Substance | C3537244; Insulins; Pharmacologic Substance
T26	PROC 1601 1612	tratamiento
#25	AnnotatorNotes T26	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T27	DISO 1640 1664	enfermedad intercurrente
#26	AnnotatorNotes T27	C0277557; Intercurrent disease; Disease or Syndrome
T28	DISO 1671 1701	diabetes gravídica gestacional
T29	PROC 1734 1745	Tratamiento
#27	AnnotatorNotes T29	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T30	CHEM 1766 1815	agonistas del receptor del péptido glucagonoide 1
T31	CHEM 1817 1822	GLP-1
T32	CHEM 1838 1847	exenatida
#28	AnnotatorNotes T32	C0167117; exenatide; Amino Acid, Peptide, or Protein · Pharmacologic Substance
T33	CHEM 1850 1861	liraglutida
#29	AnnotatorNotes T33	C1456408; liraglutide; Amino Acid, Peptide, or Protein · Hormone · Pharmacologic Substance
T34	DISO 1865 1884	Disfunción hepática
#30	AnnotatorNotes T34	C0086565; Liver Dysfunction; Finding
T35	DISO 1973 1989	Disfunción renal
#31	AnnotatorNotes T35	C0151746; Abnormal renal function; Pathologic Function | C1565489; Renal Insufficiency; Disease or Syndrome
T36	CHEM 2017 2027	creatinina
#32	AnnotatorNotes T36	C0010294; creatinine; Biologically Active Substance · Organic Chemical
T37	ANAT 2028 2034	sérica
#33	AnnotatorNotes T37	C0229671; Serum; Body Substance | C0588987; Serum product; Body Substance
T38	CHEM 2162 2172	metformina
#34	AnnotatorNotes T38	C0025598; metformin; Organic Chemical · Pharmacologic Substance
T39	DISO 2299 2302	CMT
T40	DISO 2268 2297	carcinoma medular de tiroides
#35	AnnotatorNotes T40	C0238462; Medullary carcinoma of thyroid; Neoplastic Process
T41	DISO 2309 2347	neoplasia endocrina múltiple de tipo 2
#36	AnnotatorNotes T41	C4048306; Multiple endocrine neoplasia Type 2; Neoplastic Process
T42	DISO 2349 2353	MEN2
#37	AnnotatorNotes T42	C0025268; Multiple Endocrine Neoplasia Type 2a; Neoplastic Process
T43	DISO 2373 2393	pancreatitis crónica
#38	AnnotatorNotes T43	C0149521; Pancreatitis, Chronic; Disease or Syndrome
T44	DISO 2396 2425	pancreatitis aguda idiopática
#39	AnnotatorNotes T44	C0341461; Idiopathic acute pancreatitis; Disease or Syndrome
T45	PROC 363 368	HbA1c
#40	AnnotatorNotes T45	C0202054; Glucohemoglobin measurement; Laboratory Procedure
T46	PROC 1028 1051	Índice de masa corporal
#41	AnnotatorNotes T46	C0005893; Body mass index procedure; Diagnostic Procedure | C3698309; Measurement of body mass index; Health Care Activity
T47	ANAT 1043 1051	corporal
#42	AnnotatorNotes T47	C0460148; Human body structure; Anatomical Structure | C1318419; Entire human body; Anatomical Structure
T48	CHEM 1113 1127	antidiabéticos
#43	AnnotatorNotes T48	C0935929; Antidiabetics; Pharmacologic Substance
T49	CHEM 1136 1139	ADO
#44	AnnotatorNotes T49	[antidiabéticos orales]
T50	CHEM 1530 1538	insulina
#45	AnnotatorNotes T50	C0021641; Insulin; Amino Acid, Peptide, or Protein · Hormone · Pharmacologic Substance | C3537244; Insulins; Pharmacologic Substance
T51	PROC 1912 1916	ALAT
T52	ANAT 1876 1884	hepática
#46	AnnotatorNotes T52	C0023884; Liver; Body Part, Organ, or Organ Component | C1278929; Entire liver; Body Part, Organ, or Organ Component
T53	ANAT 1984 1989	renal
#47	AnnotatorNotes T53	C0022646; Kidney; Body Part, Organ, or Organ Component | C1278978; Entire kidney; Body Part, Organ, or Organ Component
T54	PROC 2017 2034	creatinina sérica
#48	AnnotatorNotes T54	C0201976; Creatinine measurement, serum (procedure); Laboratory Procedure
T55	PROC 2188 2199	Calcitonina
#49	AnnotatorNotes T55	C0201924; Calcitonin measurement; Laboratory Procedure
T56	ANAT 2278 2285	medular
#50	AnnotatorNotes T56	C0376152; Marrow; Body Part, Organ, or Organ Component | C1550278; Medullary - body parts; Body Part, Organ, or Organ Component
T57	ANAT 2289 2297	tiroides
#51	AnnotatorNotes T57	C0040132; Thyroid Gland; Body Part, Organ, or Organ Component | C1278878; Entire thyroid gland; Body Part, Organ, or Organ Component
T58	Date 12 16	2012
T59	LIVB 155 162	sujetos
#52	AnnotatorNotes T59	C0681850; Study Subject; Group
T60	Age 343 352	≥ 18 años
T62	Duration 510 529	90 días como mínimo
T63	Frequency 561 567	diaria
T64	Duration 651 665	mínimo 56 días
T65	Frequency 698 704	diaria
T66	Duration 863 874	los 56 días
T67	Frequency 911 917	diaria
T68	Dose 941 950	≥ 1500 mg
T69	Dose 953 974	dosis máxima tolerada
#53	AnnotatorNotes T69	C0752079; Maximum Tolerated Dose; Quantitative Concept
T70	Duration 984 1003	90 días como mínimo
T72	Route 1128 1134	orales
#54	AnnotatorNotes T72	C1527415; Oral Route of Drug administration; Functional Concept
T73	Neg_cue 1142 1156	a excepción de
T74	Duration 1176 1184	≥90 días
T75	Date 1228 1234	actual
T76	Neg_cue 1257 1264	excepto
T77	LIVB 1365 1377	investigador
#55	AnnotatorNotes T77	C0035173; Research Personnel; Professional or Occupational Group
T79	PHYS 1396 1421	metabolismo de la glucosa
#56	AnnotatorNotes T79	C0596620; glucose metabolism; Molecular Function
T80	Date 1483 1489	actual
T81	Neg_cue 1522 1529	excepto
T82	Time 1563 1571	prandial
T83	Date 1613 1626	a corto plazo
T84	LIVB 1718 1730	investigador
#57	AnnotatorNotes T84	C0035173; Research Personnel; Professional or Occupational Group
T85	Date 1755 1761	actual
T86	LIVB 2069 2076	varones
#58	AnnotatorNotes T86	C0025266; Male population group; Population Group
T88	LIVB 2111 2118	mujeres
#59	AnnotatorNotes T88	C0043210; Woman; Population Group
T90	Duration 2386 2393	crónica
#60	AnnotatorNotes T90	C0205191; chronic; Temporal Concept
T91	PHYS 1680 1689	gravídica
#61	AnnotatorNotes T91	C0032961; Pregnancy; Organism Function
T61	Dose 597 637	entre 20 y 50 unidades (ambas inclusive)
T92	Dose 748 762	20-50 unidades
T71	PROC 1299 1305;1315 1331	cambio de la medicación
#62	AnnotatorNotes T71	C0948468; Drug therapy changed; Therapeutic or Preventive Procedure
T78	PHYS 1690 1701	gestacional
#63	AnnotatorNotes T78	C0032961; Pregnancy; Organism Function
T87	Dose 555 560;568 575	Dosis estable
T89	Dose 905 910;918 925	Dosis estable
T93	PROC 1201 1207	visita
#64	AnnotatorNotes T93	C1512346; Patient Visit; Health Care Activity
T94	Quantifier_or_Qualifier 1208 1209	1
A1	Assertion T16 Negated
A2	Assertion T18 Negated
A3	Assertion T19 Negated
A4	Assertion T50 Negated
A5	Status T43 History_of
A6	Status T44 History_of
A7	Status T40 History_of
A11	Status T40 Family_history_of
A8	Status T39 History_of
A12	Status T39 Family_history_of
A9	Status T41 History_of
A13	Status T41 Family_history_of
A10	Status T42 History_of
A14	Status T42 Family_history_of
A15	Status T23 History_of
A16	Status T24 History_of
A17	Status T25 History_of
A18	Status T50 History_of
A19	Status T29 History_of
A20	Status T30 History_of
A22	Status T32 History_of
A23	Status T33 History_of
#66	AnnotatorNotes T1	C0511730; Identify product efficacy and safety issues; Health Care Activity + C0008976; Clinical Trials; Research Activity
#67	AnnotatorNotes T75	C0521116; Current (present time); Temporal Concept 
#68	AnnotatorNotes T80	C0521116; Current (present time); Temporal Concept 
#69	AnnotatorNotes T85	C0521116; Current (present time); Temporal Concept 
#70	AnnotatorNotes T83	C0443303; short-term; Temporal Concept
#71	AnnotatorNotes T28	C0085207; Gestational Diabetes; Disease or Syndrome 
#72	AnnotatorNotes T51	C0001899; Alanine Transaminase; Amino Acid, Peptide, or Protein · Enzyme
#73	AnnotatorNotes T39	C0238462; Medullary carcinoma of thyroid; Neoplastic Process
R1	Negation Arg1:T73 Arg2:T16	
R2	Negation Arg1:T76 Arg2:T18	
R3	Negation Arg1:T76 Arg2:T19	
T95	Spec_cue 1379 1384	pueda
T96	CONC 1385 1392	afectar
A24	Assertion T96 Speculated
#65	AnnotatorNotes T96	C0521102; Interferes with; Functional Concept
R4	Negation Arg1:T81 Arg2:T50	
T97	Quantifier_or_Qualifier 1539 1544	basal
A25	Assertion T97 Negated
#74	AnnotatorNotes T97	C1442488; Baseline; Quantitative Concept
R5	Has_Quantifier_or_Qualifier Arg1:T50 Arg2:T97	
R6	Combined_with Arg1:T2 Arg2:T3	
R7	Experiences Arg1:T59 Arg2:T2	
R8	Experiences Arg1:T59 Arg2:T4	
R9	Experiences Arg1:T59 Arg2:T5	
T98	Result_or_Value 373 399	7,0-10,0% [53-86 mmol/mol]
R10	Has_Result_or_Value Arg1:T45 Arg2:T98	
R11	Used_for Arg1:T12 Arg2:T11	
T99	Quantifier_or_Qualifier 473 479	activo
#75	AnnotatorNotes T99	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R12	Has_Quantifier_or_Qualifier Arg1:T11 Arg2:T99	
R13	Has_Duration_or_Interval Arg1:T12 Arg2:T62	
T100	PROC 542 551	selección
#76	AnnotatorNotes T100	C0242802; Patient Selection; Research Activity
R14	Before Arg1:T11 Arg2:T100	
R15	Has_Dose_or_Strength Arg1:T13 Arg2:T87	
R16	Has_Frequency Arg1:T13 Arg2:T63	
R17	Has_Dose_or_Strength Arg1:T13 Arg2:T61	
R18	Has_Duration_or_Interval Arg1:T13 Arg2:T64	
T101	PROC 678 687	selección
#77	AnnotatorNotes T101	C0242802; Patient Selection; Research Activity
R19	Before Arg1:T13 Arg2:T101	
T102	PROC 794 803	selección
#78	AnnotatorNotes T102	C0242802; Patient Selection; Research Activity
T103	PROC 891 900	selección
#79	AnnotatorNotes T103	C0242802; Patient Selection; Research Activity
T104	CONC 692 697	dosis
#80	AnnotatorNotes T104	C0178602; Dosage; Quantitative Concept
R20	Has_Frequency Arg1:T104 Arg2:T65	
R21	Has_Dose_or_Strength Arg1:T104 Arg2:T92	
T105	CONC 784 803	día de la selección
R22	Overlap Arg1:T104 Arg2:T105	
T106	Result_or_Value 854 859	± 10%
T107	CONC 824 837	fluctuaciones
#81	AnnotatorNotes T107	C0205419; Variant; Qualitative Concept
R25	Has_Result_or_Value Arg1:T107 Arg2:T106	
R26	Overlap Arg1:T107 Arg2:T66	
R23	Before Arg1:T107 Arg2:T103	
R24	Has_Dose_or_Strength Arg1:T14 Arg2:T89	
R27	Has_Frequency Arg1:T14 Arg2:T67	
R28	Has_Dose_or_Strength Arg1:T14 Arg2:T68	
R29	Has_Dose_or_Strength Arg1:T14 Arg2:T69	
R30	Has_Duration_or_Interval Arg1:T14 Arg2:T70	
T108	PROC 1016 1025	selección
#82	AnnotatorNotes T108	C0242802; Patient Selection; Research Activity
R31	Before Arg1:T14 Arg2:T108	
T109	PROC 1211 1220	selección
#83	AnnotatorNotes T109	C0242802; Patient Selection; Research Activity
R32	Has_Quantifier_or_Qualifier Arg1:T93 Arg2:T94	
T110	PROC 2216 2225	selección
#84	AnnotatorNotes T110	C0242802; Patient Selection; Research Activity
R33	Overlap Arg1:T55 Arg2:T110	
T111	Result_or_Value 2200 2209	≥ 50 ng/l
R34	Has_Result_or_Value Arg1:T55 Arg2:T111	
R35	Location_of Arg1:T53 Arg2:T35	
R36	Location_of Arg1:T37 Arg2:T54	
T112	Result_or_Value 2035 2061	≥ 133 µmol/l (≥ 1,5 mg/dl)
R38	Has_Result_or_Value Arg1:T54 Arg2:T112	
T113	Result_or_Value 2079 2103	≥ 125 µmol/l (1,4 mg/dl)
R39	Has_Result_or_Value Arg1:T54 Arg2:T113	
R40	Experiences Arg1:T88 Arg2:T54	
R41	Experiences Arg1:T86 Arg2:T54	
R42	Experiences Arg1:T86 Arg2:T35	
R43	Experiences Arg1:T88 Arg2:T35	
R44	Experiences Arg1:T86 Arg2:T38	
R45	Experiences Arg1:T88 Arg2:T38	
R46	Location_of Arg1:T47 Arg2:T46	
R47	Location_of Arg1:T47 Arg2:T9	
T114	Result_or_Value 1058 1068	≤ 40 kg/m2
R48	Has_Result_or_Value Arg1:T46 Arg2:T114	
R49	Has_Result_or_Value Arg1:T9 Arg2:T114	
R50	Used_for Arg1:T48 Arg2:T15	
R51	Used_for Arg1:T49 Arg2:T15	
R52	Has_Route_or_Mode Arg1:T48 Arg2:T72	
R53	Has_Route_or_Mode Arg1:T49 Arg2:T72	
R54	Overlap Arg1:T48 Arg2:T74	
R55	Before Arg1:T15 Arg2:T93	
R56	Before Arg1:T15 Arg2:T109	
R57	Overlap Arg1:T17 Arg2:T75	
R58	Used_for Arg1:T20 Arg2:T71	
R60	Speculation Arg1:T95 Arg2:T96	
T115	Quantifier_or_Qualifier 1332 1344	concomitante
#85	AnnotatorNotes T115	C0521115; Simultaneous; Temporal Concept
R61	Has_Quantifier_or_Qualifier Arg1:T20 Arg2:T115	
R62	Used_for Arg1:T21 Arg2:T79	
T116	Quantifier_or_Qualifier 1448 1458	sistémicos
#86	AnnotatorNotes T116	C0205373; Systemic; Functional Concept
R64	Has_Quantifier_or_Qualifier Arg1:T22 Arg2:T116	
R66	Used_for Arg1:T24 Arg2:T23	
R67	Overlap Arg1:T24 Arg2:T80	
R68	Overlap Arg1:T25 Arg2:T82	
T117	Quantifier_or_Qualifier 1574 1585	premezclada
R69	Has_Quantifier_or_Qualifier Arg1:T25 Arg2:T117	
R70	Used_for Arg1:T25 Arg2:T23	
R71	Overlap Arg1:T25 Arg2:T80	
R72	Overlap Arg1:T25 Arg2:T83	
R73	Overlap Arg1:T24 Arg2:T83	
R74	Used_for Arg1:T24 Arg2:T26	
R75	Used_for Arg1:T25 Arg2:T26	
R76	Overlap Arg1:T28 Arg2:T91	
R77	Overlap Arg1:T28 Arg2:T78	
R78	Overlap Arg1:T30 Arg2:T85	
R80	Used_for Arg1:T30 Arg2:T29	
R82	Used_for Arg1:T32 Arg2:T29	
R83	Used_for Arg1:T33 Arg2:T29	
#87	AnnotatorNotes T31	C0061355; Glucagon-Like Peptide 1; Amino Acid, Peptide, or Protein
#88	AnnotatorNotes T30	C1562104; Product containing glucagon-like peptide 1 receptor agonist (product); Pharmacologic Substance · Hormone
R84	Location_of Arg1:T52 Arg2:T34	
T118	Result_or_Value 1917 1970	≥ 2,5 veces el límite superior de la normalidad (LSN)
R85	Has_Result_or_Value Arg1:T51 Arg2:T118	
R87	Location_of Arg1:T56 Arg2:T40	
R88	Location_of Arg1:T57 Arg2:T40	
R89	Location_of Arg1:T56 Arg2:T39	
R90	Location_of Arg1:T57 Arg2:T39	
R91	Has_Duration_or_Interval Arg1:T43 Arg2:T90	
T119	Quantifier_or_Qualifier 705 710	total
#89	AnnotatorNotes T119	C0439810; Total; Qualitative Concept
R92	Has_Quantifier_or_Qualifier Arg1:T104 Arg2:T119	
R93	Overlap Arg1:T49 Arg2:T74	
#90	AnnotatorNotes T94	C0205447; One; Quantitative Concept
#91	AnnotatorNotes T105	C2986327; Study Recruitment Status Date; Temporal Concept
A21	Experiencer T59 Patient
A26	Experiencer T77 Other
A27	Experiencer T84 Other
A28	Experiencer T86 Patient
A29	Experiencer T88 Patient
